JPRN-UMIN000017569已完成未知
The Efficacy and Safety of Brinzolamide 1%/Timolol 0.5% Fixed Combination Versus Dorzolamide 1%/Timolol 0.5 - Alcon Japan AZORGA Phase IV study
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 190
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •excerpt: (8) Patients with corneal disorder (reduced corneal endothelium cells, etc.). (9) Patients with a history of chronic, recurrent or current severe inflammatory eye disease (i.e., scleritis, uveitis, herpes keratitis) in either eye.(10) Patients with a history of ocular trauma in either eye within six (6) months prior to the screening examination.(11) Patients with ocular infection or ocular inflammation in either eye.(12) Patients with a history of or current clinically significant or progressive retinal disease such as retinal degeneration, diabetic retinopathy, or retinal detachment in either eye. (13) Patients with a history of intraocular surgery in either eye within six (6) months prior to the screening examination.(14) Patients with a history of ocular laser surgery in either eye within three (3) months prior to the screening examination. (15) Patients with any abnormality preventing reliable applanation tonometry of either eye. (16) Patients with a best-corrected visual acuity worse than 0.2 score (decimal visual acuity) in either eye(17) Patients with an angle Grade 2 or less in either eye by Shaffer classification. (18) Patients with severe visual field loss in either eye which is judged by the investigator.(19) Patients with current or history of use of any topical drug containing carbonic anhydrase inhibitor at screening visit.(20) Patients using any additional topical or systemic ocular hypotensive medication indicated for glaucoma or intraocular hypertension during the study.(21) Patients using corticosteroid medications administered by ocular or systemic route during the study.
研究者
相似试验
进行中（未招募）
不适用
Efficacy and Safety of Adding the Brinzolamide/Timolol Maleate Fixed Combination (Azarga®) in Ocular Hypertensive or Glaucoma Patients Uncontrolled on Prostaglandin MonotherapyEUCTR2010-022948-21-ATAlcon Research, Ltd.50
进行中（未招募）
不适用
Comparison of Safety and Efficacy of Brinzolamide/Timolol Fixed Combination vs COSOPT in Patients with Open-Angle Glaucoma or Ocular Hypertension - Brinzolamide/Timolol Fixed Combination vs COSOPTEUCTR2005-004766-16-BEAlcon Research, Ltd.420
进行中（未招募）
不适用
Comparison of Safety and Efficacy of Brinzolamide/Timolol Fixed Combination vs COSOPT in Patients with Open-Angle Glaucoma or Ocular Hypertension - Brinzolamide/Timolol Fixed Combination vs COSOPTOpen Angle Glaucoma or Ocular HypertensionICD: H40.1/H40.0EUCTR2005-004766-16-SEAlcon Research, Ltd.420
进行中（未招募）
不适用
Comparison of Safety and Efficacy of Brinzolamide/Timolol Fixed Combination vs COSOPT in Patients with Open-Angle Glaucoma or Ocular Hypertension. - Brinzolamide/Timolol Fixed Combination vs COSOPTOpen-Angle Glaucoma or Ocular HypertensionEUCTR2005-004766-16-LTAlcon Research, Ltd.420
进行中（未招募）
不适用
Comparison of Safety and Efficacy of Brinzolamide/Timolol Fixed Combination vs COSOPT® in Patients with Open-Angle Glaucoma or Ocular Hypertension. - Brinzolamide/Timolol Fixed Combination vs COSOPTOpen –Angle Glaucoma or Ocular HypertensionEUCTR2005-004766-16-LVAlcon Research, Ltd.420